Seventy‐Five Microgram Desogestrel Minipill, A New Perspective in Estrogen‐Free Contraception

@article{Benagiano2003SeventyFiveMD,
  title={Seventy‐Five Microgram Desogestrel Minipill, A New Perspective in Estrogen‐Free Contraception},
  author={Giuseppe Benagiano and Francesco M Primiero},
  journal={Annals of the New York Academy of Sciences},
  year={2003},
  volume={997}
}
Abstract: Progestin‐only minipills have been available for over three decades, yet their use has been limited, because of a documented lower efficacy when compared to pills that combine estrogen and progestin. The availability of a new low‐dose progestin‐only minipill containing 75 μg desogestrel (DSG) offers a new perspective, since, in a large multicenter study, this minipill gave a crude Pearl index of 0.41 and an adjusted one of 0.14, which is comparable to indicies found in clinical trials… 
Pharmacokinetic evaluation of desogestrel as a female contraceptive
TLDR
This is a review of the available data on the pharmacokinetics of DSG and ETN in hormonal contraception and its metabolite ETN is the compound of choice.
Drug safety evaluation of desogestrel
TLDR
Although DSG is efficacious in HRT, it may not represent the best choice due to the potential higher risk of breast cancer compared with progesterone or dydrogesterone.
Role of progestins in contraception
TLDR
Progestin‐only contraceptives may be preferable in some situations, which have absolute or relative contraindications to estrogen, side‐effects to estrogen containing hormonal contraception, lactation, and comfort and feasibility of formulations for long‐term use.
Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation
TLDR
The ovulation-inhibiting effect of various orally administered estrogen-progestin combinations (combined oral contraceptives [COCs]) are examined for their components alone or in the various combined formulations, with special emphasis on products containing natural estrogens.
Oral and depot progestin therapy for endometriosis: towards a personalized medicine
TLDR
Progestins are effective in controlling pain symptoms in the majority of women with endometriosis, and their effect seems not inferior to that achieved with other compounds used to treat the disease, such as gonadotropin-releasing hormone agonist.
Recent advances in hormonal contraception
  • R. Erkkola
  • Medicine
    Current opinion in obstetrics & gynecology
  • 2007
TLDR
There are more contraceptive choices available than ever before and to educate healthcare providers as to the methods available and to inform and educate consumers are cornerstones for successful contraception.
Randomized, Crossover and Single-Dose Bioquivalence Study of Two Oral Desogestrel Formulations (Film-Coated Tablets of 75 μg) in Healthy Female Volunteers
TLDR
It can be concluded that test formulation of desogestrel 75 μg is bioequivalent to the reference formulation (Cerazet® 75 μg, Organon Española S.A.).
Contraceptive efficacy and safety of DMPA-SC.
TLDR
DMPA-SC offers women a new, highly effective and convenient long-acting contraceptive option and adverse events were similar to those reported previously with Depo-Provera IM.
Vascular dysfunction as a cause of endometrial bleeding
  • D. Archer
  • Medicine
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2012
TLDR
Heavy menstrual bleeding and the spotting and bleeding associated with the use of hormonal contraceptives are distinct entities affecting endometrial vasculature and hemostasis and there is no effective treatment for the S/B associated with hormonal contraceptives.
Selective progesterone receptor modulators 2: use in reproductive medicine
TLDR
Few applications outside pregnancy seem worthy of large-scale use: emergency contraception and long-term medical management of uterine fibroids and possibly of endometriosis.
...
1
2
3
4
...

References

SHOWING 1-10 OF 34 REFERENCES
New progestogens in oral contraception.
TLDR
This review examines in detail the clinical efficacy of the new COCs, where possible in comparison with those containing levonorgestrel or norethisterone, and their pharmacological effect on carbohydrate and lipid metabolism, haematological factors, pituitary-ovarian function and serum protein and androgen concentrations.
Hormonal effects of the 300 μg norethisterone (NET) minipill
TLDR
It is concluded that the relative length of follicular and luteal phases has a predictive value for the expected ovarian reaction to the NET minipill and the efficacy of the minipills might be increased by judicious selection of women exhibiting, during the pretreatment period, a high follicular to luteAl phase (F L ) ratio.
A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and levonorgestrel 30 μg daily
TLDR
A randomized double blind group comparative study was performed to compare inhibition of ovulation during the use of two (progestogen-only) oral contraceptives containing doses of 75 mcg desogestrel or 30 mcg levonorgestrel.
Laboratory and Clinical Assessment of a New Progestational Compound, Desogestrel
TLDR
The results of the study have not revealed any adverse effects on laboratory or clinical parameters and justify further clinical investigations with desogestrel, both alone and in combination with ethinylestradiol.
Low doses of progestogen as an approach to fertility control.
TLDR
Preliminary studies of ovarian biopsy specimens suggest that ovulation occurs as in cyclic treatment, and the endometrium showed less evidence of normal secretory activity than that seen with cyclic administration of the same drug.
The effects of two progestogen-only pills containing either desogestrel (75 μg/day) or levonorgestrel (30 μg/day) on lipid metabolism
TLDR
It can be concluded that the POP containing 75 μg desogestrel has a negligible effect on lipid metabolism, Despite the higher progestogen dose, the effect of this new POP is similar to that of a traditional POP containing 30 μg levonorgestrel.
Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses.
TLDR
The 75 microgram dose of desogestrel is the most promising dose for the development of a new progestogen-only oral contraceptive agent.
The effects of two progestogen-only pills containing either desogestrel (75 μg/day) or levonorgestrel (30 μg/day) on carbohydrate metabolism and adrenal and thyroid function
TLDR
The effects of both progestogen-only pills on carbohydrate metabolism were minimal and considered to be clinically insignificant, and with regard to adrenal and thyroid function, the effects of desogestrel were not significantly different from those of levonorgestrel.
Comparative study of the effects of a progestogen‐only pill containing desogestrel and an intrauterine contraceptive device in lactating women
Objective To evaluate the effects of desogestrel 75μg/day, as a progestogen‐only pill compared with a copper‐bearing intrauterine contraceptive device (IUCD) on lactation and to study the safety of
Effectiveness of an oral contraceptive; effects of a progestin-estrogen combination upon fertility, menstrual phenomena, and health.
TLDR
830 patients receiving 1 oral contraceptive tablet/day from Cycle Days 5 through 24 were studied for effects upon fertility menstrual phenomena and health and an inconsistent change in the amount of cervical erosion and no pathological changes of the adnexae or vagina were noted.
...
1
2
3
4
...